CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2006--Molecular Insight Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Ultratrace MIBG (iobenguane I 131) for the treatment of neuroendocrine tumors such as carcinoid, neuroblastoma, and pheochromocytoma. Ultratrace MIBG is a targeted radiopharmaceutical that is designed to maximize delivery of radiolabeled MIBG molecules so that neuroendocrine tumors can be effectively diagnosed and treated, and to minimize the amount of non-radioactive MIBG molecules that are delivered in the drug. The compound is currently in preclinical development and an Investigational New Drug application (IND) is currently under review at FDA.
